XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Moderna Collaboration and License Agreement - Narratives (Details)
$ in Millions
1 Months Ended 6 Months Ended
Jan. 31, 2022
USD ($)
target
product
representative
Jun. 30, 2023
USD ($)
obligation
Collaboration and License Agreement | Research and Development Services    
Moderna Collaboration and License Agreement    
Upfront payment $ 45.0  
Variable consideration $ 73.9  
Term of contract 5 years  
Noncurrent portion of deferred revenue $ 45.0  
Collaboration and License Agreement | Moderna    
Moderna Collaboration and License Agreement    
Maximum of Research Targets | target 12  
Number of representatives from each company in joint steering committee | representative 3  
Collaboration and License Agreement | Moderna | Research and Development Services    
Moderna Collaboration and License Agreement    
Upfront non-refundable payment received $ 45.0  
Minimum commitment to reimburse research and development costs $ 10.0  
Period of reimbursement of research and development costs 3 years  
Number of products developed and commercialized | product 12  
Number of performance obligations | obligation   2
Collaboration and License Agreement | Moderna | Minimum | Research and Development Services    
Moderna Collaboration and License Agreement    
Amount receivable per product $ 247.0  
Collaboration and License Agreement | Moderna | Maximum | Research and Development Services    
Moderna Collaboration and License Agreement    
Amount receivable per product $ 253.0  
Moderna License Agreement    
Moderna Collaboration and License Agreement    
Collaboration revenues   $ 16.6